Rite Aid has announced Reliance ACO, based in southeast Mich., as the latest healthcare provider to join its Rite Aid Health Alliance initiative.
The DEA announced on Tuesday that the 10th National Prescription Drug Take-Back will take place across the United States on Sept. 26 — except for in Pennsylvania and Delaware where the event will take place on Sept. 12.
The National Association of Boards of Pharmacy and its member state boards of pharmacy are planning to enhance several of its examination and assessment programs to better reflect the evolving practice of pharmacy. Changes will begin in November 2015.
Among the nearly 400 manufacturers, automation, sofware and pharmacy business vendors on the trade show foor at the Cardinal Health Retail Business Conference this week were several important pharmacy solutions.
The Consumer Healthcare Products Association expressed support for the DXM Abuse Prevention Act, introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson, R-Ohio, and Doris Matsui, D-Calif., on Wednesday.
Customer Appreciation Night: Through the Decades was a celebration of 25 years at RBC. With surprises around every corner, this celebration allowed customers to turn back time. The celebration included dinner, dessert and a "Through the Decades" show.
Hikma Pharmaceuticals on Wednesday announced its acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane (together, “Roxane” — an American specialty generics company) from Boehringer Ingelheim for about $2.65 billion.
Voters from all political parties support sunshine legislation that would make promote transparency in generic prescription drug payments by pharmacy benefit manager corporations, according to a national survey from the National Community Pharmacists Association released Tuesday.
In its largest acquisition to date, medical equipment manufacturer Drive Medical acquired DeVilbiss Healthcare from Vestar Capital Partners in early July.
Sandoz on Tuesday announced the launch of a generic version of AstraZeneca’s Pulmicort Respules (budesonide inhalation suspension) in 1-mg strength. Sandoz expects to have 180-day generic drug marketing exclusivity for the 1-mg strength.